BioCentury | Feb 16, 2018
Clinical News

Brickell's sofpironium bromide meets in Phase IIb for hyperhidrosis

...patients with primary axillary hyperhidrosis showing that 5%, 10% and 15% gel formulations of sofpironium bromide (BBI-4000...
...improvement in HDSM-Ax vs. vehicle (p<0.0001 and p<0.001, respectively). On secondary endpoints, all doses of sofpironium bromide...
...anticholinergic. Brickell Biotech Inc., Boulder, Colo. Kaken Pharmaceutical Co. Ltd. (Tokyo:4521), Tokyo, Japan Product: Sofpironium bromide (BBI-4000...
BioCentury | Jan 4, 2016
Clinical News

Sofpironium bromide: Phase IIb data

...A double-blind, U.S. Phase IIb trial in 189 patients with primary axillary hyperhidrosis showed that BBI-4000...
...from baseline to week4 vs. vehicle-treated controls. Additionally, a significantly greater proportion of patients receiving BBI-4000...
...Biotech Inc. , Miami, Fla. Kaken Pharmaceutical Co. Ltd. (Tokyo:4521), Tokyo, Japan Product: Sofpironium bromide ( BBI-4000...
BioCentury | Feb 16, 2015
Clinical News

BBI-4000: Phase IIb started

...began a double-blind, vehicle-controlled, U.S. Phase IIb trial to evaluate 3 dose levels of topical BBI-4000...
...daily for 4 weeks in about 180 patients. Brickell Biotech Inc. , Miami, Fla. Product: BBI-4000...
BioCentury | Mar 11, 2013
Company News

AmorePacific, Brickell Biotech deal

...BBI-3000, a topical/oral retinoid X receptor ( RXR ) agonist for acne and psoriasis; and BBI-4000...
Items per page:
1 - 4 of 4